| Not Yet Recruiting | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer | Phase 1 | 2026-02-01 |
| Recruiting | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification | Phase 1 | 2025-12-30 |
| Active Not Recruiting | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult | Phase 1 / Phase 2 | 2025-01-22 |
| Active Not Recruiting | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Sm SSM, Mastocytosis, Indolent, Mastocytosis, Systemic | Phase 2 | 2022-06-27 |
| Active Not Recruiting | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | Phase 3 | 2022-04-14 |
| Recruiting | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL) | Phase 2 | 2021-11-09 |
| Terminated | Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tum Solid Tumor, HER-2 Protein Overexpression | Phase 1 | 2019-03-13 |
| Terminated | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 1 | 2018-02-22 |
| Terminated | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Lymphoma | Phase 1 | 2017-10-04 |
| Terminated | Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product B Cell Lymphomas, Multiple Myeloma, Solid Tumor | — | 2016-10-01 |
| Completed | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Lymphoma | Phase 1 | 2016-08-01 |
| Completed | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Suniti Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | 2015-03-06 |
| Available | Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mast Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive | — | — |
| Available | Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stroma Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | — | — |